TACE after surgery for high-risk liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether a liver-directed treatment called TACE (transarterial chemoembolization) after surgery can help prevent liver cancer from coming back in people with high-risk features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had surgery to remove your liver cancer, and the cancer was confirmed as hepatocellular carcinoma (HCC).
- You are generally active and able to do light work (ECOG score 0 or 1).
- Your liver function is good (Child-Pugh class A or B7).
- You have at least one high-risk factor for the cancer coming back (e.g., tumor >5 cm, multiple tumors, or blood vessel invasion).
- You have not had any previous cancer treatment for your liver cancer before this surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines a procedure called TACE (which blocks the blood supply to the tumor) with surgery to remove a large liver tumor. It is for people newly diagnosed with a large liver cancer that hasn't spread and can be completely removed with surgery.
This trial tests a combination of treatments for liver cancer that cannot be removed with surgery. It uses a procedure to block the tumor's blood supply plus two drugs that help the immune system fight the cancer. This may help shrink tumors and slow the disease.
This trial is collecting information on how well a treatment (likely TACE, a procedure to block the tumor's blood supply) works for people with liver cancer that cannot be removed by surgery. It aims to see how safe and effective it is for patients who haven't had treatment before or who have a first recurrence.
This trial studies a treatment approach (a combination given through the liver) for people with early liver cancer that can be surgically removed but has a high chance of coming back. It may help reduce the risk of recurrence after treatment.
This trial tests a combination of targeted therapy (lenvatinib), immunotherapy (PD-1 inhibitor), and a procedure called TACE (which delivers chemotherapy directly to the liver tumor) for people whose liver cancer has ruptured. The goal is to stop bleeding and shrink the tumor.
This trial tests whether combining TACE (a liver-targeted chemo procedure) with two medicines—an immune “checkpoint” drug and a blood-vessel blocking drug—can control unresectable hepatocellular carcinoma. It’s designed for people who can’t have surgery or curative ablation, and who still have reasonably strong liver and overall health.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.